Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2600115949) titled 'Teniposide + Bevacizumab: A Phase II Study on Efficacy and Safety in Recurrent Glioblastoma' on Jan. 4.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Henan Cancer Hospital
Condition:
recurrent glioblastoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-01-10
Target Sample Size: Single arm :33;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=296260
Disclaimer: Curated by HT Syndication....